previously showed (and now further support in their present study) that tagged Klf1 interacts directly in vivo with the mouse embryonic β-like globin gene promoter only in primitive cells and then switches to bind the adult β-globin promoter only in definitive cells 11 . However, Klf1 is not necessary for expression of embryonic or fetal globin, so does its interaction with the embryonic/fetal promoter simply play a role in establishing its most optimal transcriptional activity before the final switch? How does the eightfold lower in vitro affinity of KLF1 for the γ-versus β-CACCC element 12 play into this scenario? Might it enable a quick release when the β-site becomes available? Also, if KLF1 knockdown is used to increase γ-globin expression in a therapeutic setting, as suggested by both studies, will that compromise β-globin expression, or is that actually a desirable outcome in individuals with sickle cell anemia but not β-thalassemia? Finally, do changes in KLF1 modification status, which are known to affect subsequent protein interactions, impinge on its role in switching? How does the Nan mutation fit into these schemes?
human cells causes a decrease in BCL11A levels and an increase in γ-globin levels, similar to the changes seen in the mouse knockdown model.
The results from these two studies support three conclusions. First, HPFH can result from KLF1 haploinsufficiency. Second, KLF1 indirectly regulates γ-globin expression by directly regulating BCL11A. Third, subtle variation in KLF1 levels can lead to key changes in gene expression output. Zhou et al. 4 noted that levels of Klf1 are increased approximately threefold in mouse adult definitive erythroid cells compared to embryonic primitive erythroid cells and suggested that this contributes to the developmental changes in β-like globin expression. Together, these results suggest that KLF1 has a critical role in regulating globin switching-both in activating β-globin and in repressing γ-globin-and tie the two major globin switching proteins in an interactive model (Fig. 1 ).
More to come?
These studies raise a number of intriguing questions. First, Townes and colleagues variable evolutionary signatures at the heart of enhancers
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what is the best way to identify regulatory dna sequences such as enhancers, promoters, insulators and silencers? a new study shows that specific binding by a coactivator protein identifies enhancers that are invisible to common detection methods based on evolutionary constraint.
Much effort has been devoted to accurately predicting the regulatory DNA sequences required for correct gene expression. Unfortunately, molecular biologists and biochemists are struggling to develop even a rudimentary set of rules that can identify regulatory modules using only DNA sequence data. Comparisons of homo logous DNA between related species have provided a valuable approach for identifying regulatory sequences. Thousands of human noncoding DNA sequences have sustained very few alterations over vertebrate evolution, showing that they are under stringent evolutionary were specifically bound by this coactivator were identified and nominated as candidate heart-specific enhancers.
Blow et al. found two important features of the candidate heart enhancers. First, 75% of candidate sequences were validated as enhancers in vivo; and of these validated enhancers, the vast majority (84%) were active in the developing heart. Second, these candidate heart enhancers differed dramatically from other tissue-specific enhancers in their evolutionary signatures. Most of the heart enhancers were not subject to the stringent evolutionary constraint that is characteristic of forebrain enhancers active at the same developmental time point. Although 65% of heart enhancers were detectably conserved in placental mammals, over half (56%) of the forebrain enhancers were more deeply conserved in birds, with some even being conserved in amphibians and fish (Fig. 1) . constraint 1 . Many of these sequences are enhancers of expression in some tissues, such as brain tissue (Fig. 1, ref. 2). However, enhancers active in other tissues, such as heart tissue, are rarely found by this approach. A new study on p. 806 of this issue by Len Pennacchio and colleagues 3 uses the presence of a transcriptional coactivator bound to DNA to identify heart enhancers. They show that many regulatory sequences are preserved over a limited phylogenetic distance and suggest that the pattern of evolutionary constraint may vary by tissue type.
Variability in evolutionary constraint
Blow et al. 3 identified DNA segments bound by the common transcriptional coactivator protein p300 in mouse embryonic heart tissue by chromatin immunoprecipitation. After deep sequencing of the DNA associated with p300, approximately 3,600 DNA segments that phylogenetic distance comparable to that of species having hearts. However, at least for the enhancers described to date, that is not the case. Is the pattern of heart gene regulation actually well preserved in vertebrates or does it vary? If it is well preserved, are the heart-specific enhancers reinvented independently in different lineages? What evolutionary mechanisms provide the sequence changes that could fuel that reinvention? What evolutionary profiles dominate in enhancers for other tissues? These are but a few of the questions raised by these recent results. Happily, many of these questions should be answerable with the growing number of genomic analyses of gene regulation. The answers resulting from these analyses should deepen our understanding of gene regulation in complex organisms and improve our ability to interpret genetic variation affecting gene regulation in humans.
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The author declares no competing financial interests. and others showing highly localized constraint (for example, those in certain binding sites for particular transcription factors) 6, 8 . Could it be that the level of constraint on enhancers is a characteristic of particular biological properties of regulatory modules? Perhaps enhancers active in some tissues may be subject to strong constraint, whereas those active in other tissues may be evolving more rapidly. Certainly, DNA sequences regulating genes whose products are subject to positive selection, that is, those providing an adaptive advantage, would be expected to change as well and not be strongly constrained. If evolutionary profiles in regulatory regions prove to be truly distinctive for functional categories of target genes or patterns of tissue-specific expression, comparative genomics of regulatory regions will be very useful for deducing aspects of the function of these regions.
Biological implications
Interpreting this apparent tissue specificity in the levels of constraint on regulatory DNA sequences is a formidable challenge. For instance, it is not at all clear why enhancers leading to heart-specific gene expression would be evolving more rapidly than those leading to forebrain expression. The heart is an ancient organ and is obviously critical to organisms that have one. One might thus have expected that the mechanisms of gene regulation leading to heart formation would be preserved over a Figure 1 Binding by the transcriptional coactivator p300 identifies enhancers that are not conserved in all vertebrates. Left, deep phylogenetic conservation of noncoding DNA is one method for finding tissue-specific developmental enhancers, as assayed in transient transgenic mice. Such evolutionarily constrained enhancers are evident in some tissues, such as brain, but not in others, such as heart. Right, direct binding by the coactivator p300 identifies tissue-specific enhancers that are not necessarily deeply conserved (that is, conserved only in placental mammals). Lines after each species indicate that sequences homologous to the mouse enhancer are present in that species.
Clearly, stringent constraint is not a feature shared by all regulatory regions, so other approaches are required to identify these sequences in the genome. In fact, genomewide mapping studies of biochemical features associated with gene regulatory regions 4, 5 are becoming the method of choice for finding regulatory sequences.
The results from Blow et al. 3 and related work point to a complicated pattern of evolutionary constraint. The profile of evolutionary constraint, at least at the developmental time point investigated in the study, appears to be specific to enhancers from different tissues, with heart enhancers being under weak constraint, forebrain enhancers being under strong constraint, and enhancers in other tissues showing an intermediate pattern of constraint. Previous work has suggested that the evolutionary patterns of regulatory regions can provide predictive power about other aspects of their functions; for example, rapidly evolving sequences are implicated in adaptive responses 6 . Thus, even as biochemical features take the forefront in predicting regulatory regions, detailed studies of their evolutionary signatures, as revealed by alignments of DNA from multiple species across a wide phylogenetic spectrum, will continue to illuminate aspects of DNA function.
Value of interspecies alignments
One may wonder if there is any role left for comparative sequence analysis in studying regulatory regions. For a given DNA sequence that acts as a regulatory module in humans, how frequently do homologs in other species serve a similar function? Recent investigations of specific binding by liver transcription factors in five vertebrate species have shown that occupancy of a small minority (10%-22%) of the bound sites is shared between two different mammalian species 7 . This indicates that much of the binding of transcription factors is species specific, suggesting that some of the bound sites may be evolving adaptively. Perhaps many of the bound sites are playing a passive role (for example, storage) and may be evolving close to neutrally.
Indeed, previous studies of tissue-specific enhancers found many sequences that were not subject to strong evolutionary constraint across the entire tissue-specific regulatory module, with some enhancers being species specific
